GSK and Shionogi have agreed with Pfizer to restructure ViiV Healthcare’s shareholder base, with Shionogi replacing Pfizer’s 11.7 percent economic interest and increasing its stake to 21.7 percent, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback